Pharvaris (PHVS) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Key clinical results and product development

• Achieved two phase III successes for deucrictibant, including strong efficacy in HAE prophylaxis and on-demand settings.

• Deucrictibant is the only orally available B2 receptor antagonist, suitable for both on-demand and prophylactic use in HAE.

• Phase III data showed 87% attack rate reduction in type 1 and 2 HAE patients, outperforming phase II results.

• Extended-release formulation contributed to improved efficacy and broader patient coverage, including diverse global populations.

• Type 3 HAE patients included in the study showed significant improvement, with some achieving up to 90% reduction in attacks.

Safety and tolerability insights

• Only one serious adverse event reported (laryngeal dyskinesia), which was not related to laryngeal attack and resolved without issue.

• No bilirubin elevation observed in patients with grade 3 LFT elevations; both were asymptomatic.

• Hepatic enzyme elevations are consistent with background rates in HAE populations, especially those with prior androgen use.

• Safety profile is comparable to other HAE prophylactic treatments, with no unique hepatotoxicity concerns identified.

Commercial strategy and launch plans

• On-demand launch targeted for April next year, with prophylaxis launch to follow regulatory review.

• Early disease state education campaigns have built awareness and prepared the market for launch.

• Pricing strategy will consider both on-demand and prophylactic indications to maximize portfolio value.

• U.S. field force will be fully established from day one, leveraging experience from previous HAE launches.

• Ex-U.S. strategy focuses on market access and efficient resource allocation, with smaller teams in key countries.